| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Gynecologic Oncology, the Department of Obstetrics and Gynecology the Department of Pathology, UCLA School of Medicine; and The Center for Ovarian Cancer, The UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
Abstract
Forty-seven patients with stage III or IV invasive epithelial carcinoma of the ovary underwent primary cytoreductive surgery at UCLA during the five-year period 1974 to 1979. Optimal cytoreductive (defined as largest residual tumor mass 1.5 cm or less in diameter) was achieved in 31 patients (66%), including ten of 14 (71%) who underwent laparotomy and biopsy before referral. Median survival for the suboptimal group was six months, compared with 18 months for patients whose largest residual disease was 0.5 to 1.5 cm, and 40 months if residual nodules were less than 0.5 cm (P<.001). All patients in the suboptimal group died of disease within 18 months, whereas five patients (16%) in the optimal group were alive without evidence of disease from 22 months to seven years and four months postoperatively. Given the limited ability of chemotherapy to cure ovarian cancer, and the acceptable morbidity of extended operation, the availability of ideal initial surgical effort for patients with advanced stage disease may be the most important variable in current ovarian cancer care. Optimal cytoreduction is most effective in prolonging survival in patients first seen without clinical ascites or large metastatic disease.
This article has been cited by other articles:
|
|
 |
|
  A. N. Fader and P. G. Rose Role of Surgery in Ovarian Carcinoma J. Clin. Oncol., July 10, 2007; 25(20): 2873 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Panici, A. De Vivo, F. Bellati, N. Manci, G. Perniola, S. Basile, L. Muzii, and R. Angioli Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Ann. Surg. Oncol., March 1, 2007; 14(3): 1136 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhoola and W. J. Hoskins Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol., June 1, 2006; 107(6): 1399 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Krasner, M. Roche, N. S. Horowitz, J. G. Supko, S. I. Lee, and E. Oliva Case 11-2006 -- A 54-Year-Old Woman with a Mass in the Pelvis N. Engl. J. Med., April 13, 2006; 354(15): 1615 - 1625. [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Panici, A. Maggioni, N. Hacker, F. Landoni, S. Ackermann, E. Campagnutta, K. Tamussino, R. Winter, A. Pellegrino, S. Greggi, et al. Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial J Natl Cancer Inst, April 20, 2005; 97(8): 560 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Rose, S. Nerenstone, M. F. Brady, D. Clarke-Pearson, G. Olt, S. C. Rubin, D. H. Moore, J. M. Small, and the Gynecologic Oncology Group Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma N. Engl. J. Med., December 9, 2004; 351(24): 2489 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tingulstad, F. E. Skjeldestad, and B. Hagen The Effect of Centralization of Primary Surgery on Survival in Ovarian Cancer Patients Obstet. Gynecol., September 1, 2003; 102(3): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tingulstad, F. E. Skjeldestad, T. B. Halvorsen, and B. Hagen Survival and Prognostic Factors in Patients With Ovarian Cancer Obstet. Gynecol., May 1, 2003; 101(5): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Alcazar, M. J. Galan, C. Ceamanos, and M. Garcia-Manero Transvaginal Gray Scale and Color Doppler Sonography in Primary Ovarian Cancer and Metastatic Tumors to the Ovary J. Ultrasound Med., March 1, 2003; 22(3): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Morice, D. Brehier-Ollive, A. Rey, D. Atallah, C. Lhomme, P. Pautier, C. Pomel, S. Camatte, P. Duvillard, and D. Castaigne Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study Ann. Onc., January 1, 2003; 14(1): 74 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis J. Clin. Oncol., March 1, 2002; 20(5): 1248 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E.L. van der Burg, M. van Lent, M. Buyse, A. Kobierska, N. Colombo, G. Favalli, A. J. Lacave, M. Nardi, J. Renard, S. Pecorelli, et al. The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer N. Engl. J. Med., March 9, 1995; 332(10): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Berek Interval Debulking of Ovarian Cancer -- An Interim Measure N. Engl. J. Med., March 9, 1995; 332(10): 675 - 677. [Full Text]
|
|
|
|
|
|
S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., November 18, 1993; 329(21): 1550 - 1559. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
